VBIV - VBI Vaccines EV/EBITDA Multiple

The VBI Vaccines Inc. (VBIV) ecosystem relies on innovative VLP technologies that mimic viral structures to enhance immunity. In a crowded hepatitis drug market, the company is betting on government contracts and emerging regions. This chart on GURU.Markets shows an EV/EBITDA multiple of . The business is currently scaling its eVLP platform, aiming to secure a dominant position in virology through the launch of the PreHevbrio vaccine.
Analytical breakdowns for VBI Vaccines Inc.

The multiple compares the total enterprise value, including debt, against its earnings before interest, taxes, depreciation, and amortization. This metric serves as a long-term stress-testing tool, identifying asset stagnation or maturity through volatility analysis. The EV/EBITDA ratio on the price chart confirms the efficiency of the VBI Vaccines Inc. (VBIV) model, where the combination of proprietary developments and external serial production optimizes capital expenditures.